Business Context and Reporting Period
Company: Redhill Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: April 1, 2020
Context: This filing incorporates the Notice and Proxy Statement for the Annual General Meeting of Shareholders scheduled for May 4, 2020. The Company is a biopharmaceutical firm focused on the development and commercialization of products, including its lead product, RedHale (levosalbutamol sulfate inhalation solution). The filing details 14 proposals for shareholder approval, primarily concerning governance, executive compensation, and equity plan amendments.
Key Financial Metrics
Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the current period. These figures are referenced as being available in the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2019.
Capital Structure:
- Outstanding Shares (as of March 31, 2020): 352,695,668 Ordinary Shares (represented by 35,269,566 ADSs).
- Authorized Share Capital (Current): NIS 6 million (594 million Ordinary Shares + 6 million Preferred Shares).
- Proposed Authorized Share Capital: NIS 8 million (794 million Ordinary Shares + 6 million Preferred Shares).
- Shares Available for Issuance: Approximately 182,097,884 Ordinary Shares (approx. 30% of current authorized capital) as of March 31, 2020.
Material Changes and Proposals
The filing outlines significant changes to corporate governance and compensation structures to be voted on by shareholders:
- Executive Leadership: Approval of Dror Ben-Asher's engagement as both Chairman of the Board and Chief Executive Officer for a three-year term.
- Compensation Policy: Increase in the maximum annual premium for Directors and Officers (D&O) insurance from $1 million to $2 million due to market conditions.
- Equity Plan Amendment: Increase in the number of Ordinary Shares reserved for the Amended and Restated Award Plan (2010) by 7,873,940 shares, bringing the total to 59,206,448 shares (15% of fully diluted capital). The plan will now automatically increase annually to maintain this 15% threshold.
- Executive Compensation Revisions:
- Mr. Rick D. Scruggs (CCO): Salary increase to $600,000 annually (effective April 1, 2020) and a grant of 75,000 ADS options. This salary exceeds the CEO's base salary, requiring special shareholder approval.
- Mr. Dror Ben-Asher (CEO/Chairman): Grant of 90,000 ADS options.
- Non-Executive Directors: Grant of 9,000 ADS options each to seven non-executive directors.
- Option Repricing and Extension:
- Extension: Extension of the exercise period for certain options held by directors and the CEO until 2023.
- Repricing: Repricing of outstanding options held by directors and the CEO to 50% of the current exercise price (with a floor of $6.00, potentially lowering to $5.00 or $4.30 based on future revenue/EBITDA milestones).
Guidance, Outlook, and Risks
Management Commentary: Management justifies the compensation increases and option repricing as necessary to attract, retain, and motivate key personnel, particularly given the Company's focus on U.S. commercialization activities and the significant contribution of leadership to recent strategic milestones. The repricing is attributed to the fact that current option exercise prices significantly exceed the market price of ADSs.
Risks and Contingencies:
- Market Conditions: The increase in D&O insurance premiums is attributed to a rise in class action lawsuits against U.S. public companies and insurers limiting exposure in the life science sector.
- Performance Milestones: The repricing of options includes contingent clauses where the exercise price could be further reduced if the Company achieves specific net revenue or negative EBITDA targets in 2020, 2021, or 2022.
- Shareholder Approval: Several proposals (including CEO/Chairman dual role, specific compensation packages, and option repricing) require a majority vote of non-controlling shareholders without a personal interest, or a limit on votes against by such shareholders (2% threshold).
Investor Verification Checklist
- Financial Health: Review the Form 20-F for the fiscal year ended December 31, 2019, to verify cash reserves, burn rate, and liquidity, as this filing contains no financial statements.
- Option Repricing Impact: Assess the dilution impact of the proposed repricing of options for directors and the CEO, and the potential further reduction in exercise price based on future performance milestones.
- Compensation Alignment: Verify the rationale for the CCO's salary exceeding the CEO's salary and the specific performance metrics tied to the option repricing.
- Capital Availability: Confirm the necessity of the proposed increase in authorized share capital (from NIS 6M to NIS 8M) for future fundraising or M&A activities.
- Voting Requirements: Understand the specific voting thresholds required for "interested" proposals under Israeli Companies Law, which may differ from standard majority votes.